Skip to search formSkip to main contentSkip to account menu

JAK2 NP_004963.1:p.V617X

Known as: JAK2 NP_004963.1:p.Val617Xxx, JAK2 p.V617, NP_004963.1:p.Val617Xxx 
A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by another amino acid… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Badaloo, A., Jackson, A.A. & Jahoor, F. (1989) Whole body protein turnover and resting metabolic rate in homozygous sickle cell… 
2013
2013
Emerging evidence indicates that JAK2-STAT3 signaling is frequent in DLBCL cell lines and half of the activated B cell –like (ABC… 
2010
2010
A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of… 
Review
2008
Review
2008
The thrombotic and hemorrhagic diathesis represents a frequent complication in myeloproliferative disorders (CMPD). They are… 
2007
2007
Recently MPLW515 mutations have been reported in osteomyelofibrosis (OMF) and essential thrombocythemia (ET). To further evaluate… 
2007
2007
Context. Some of the luminous Compact Binary Supersoft X-Ray sources (CBSS) have shown indications of jets, also called… 
2007
2007
BackgroundThe chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders.AimsThe incidence of JAK2… 
Highly Cited
2006
Highly Cited
2006
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis 
2006
2006
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in…